Krystal Biotech Inc KRYS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if KRYS is a good fit for your portfolio.
News
-
Krystal Biotech to Present at BofA Securities 2024 Health Care Conference
-
Krystal Biotech Announces First Quarter 2024 Financial Results and Provides Business Updates
-
Krystal Biotech to Present at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting
-
Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024
-
Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung
-
Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting
-
Thinking about buying stock in GameStop, Equinix, Lyra Therapeutics, Krystal Biotech, or KULR Technology?
-
Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference
Trading Information
- Previous Close Price
- $154.82
- Day Range
- $155.83–159.73
- 52-Week Range
- $86.03–189.97
- Bid/Ask
- $63.79 / $253.55
- Market Cap
- $4.55 Bil
- Volume/Avg
- 141,454 / 387,368
Key Statistics
- Price/Earnings (Normalized)
- 655.18
- Price/Sales
- 46.22
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 229
- Website
- https://www.krystalbio.com
Comparables
Valuation
|
Metric
|
KRYS
|
CBAY
|
VRDN
|
|---|---|---|---|
Price/Earnings (Normalized) | 655.18 | — | — |
Price/Book Value | 5.53 | 12.65 | 2.44 |
Price/Sales | 46.22 | 111.01 | 2,519.75 |
Price/Cash Flow | — | — | — |
Price/Earnings
KRYS
CBAY
VRDN
Financial Strength
|
Metric
|
KRYS
|
CBAY
|
VRDN
|
|---|---|---|---|
Quick Ratio | 12.29 | 10.70 | 17.93 |
Current Ratio | 12.66 | 10.96 | 18.26 |
Interest Coverage | — | −5.27 | −137.76 |
Quick Ratio
KRYS
CBAY
VRDN
Profitability
|
Metric
|
KRYS
|
CBAY
|
VRDN
|
|---|---|---|---|
Return on Assets (Normalized) | 1.37% | −30.06% | −42.76% |
Return on Equity (Normalized) | 1.45% | −51.97% | −82.42% |
Return on Invested Capital (Normalized) | −2.24% | −30.87% | −50.70% |
Return on Assets
KRYS
CBAY
VRDN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Lrytsdfn | Ggpj | $586.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Pwqqtnrzb | Xkfhmk | $110.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Tcvbkqxty | Tdphqp | $107.6 Bil | |
MRNA
| Moderna Inc | Xgtlkltxg | Dpnc | $48.2 Bil | |
BNTX
| BioNTech SE ADR | Wqkklll | Bkk | $22.2 Bil | |
ARGX
| argenx SE ADR | Vpzvmjmth | Dvmh | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Qyhrzrppw | Jxlct | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Thzzrrpq | Dkvnf | $15.1 Bil | |
INCY
| Incyte Corp | Qcdcjqdpd | Xgqrvz | $12.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Lktqbtdrh | Tnzygq | $12.7 Bil |